Final results from Phase 1 trial of OGX-427 for treating solid tumors presented at AS

[News]

OncoGenex Pharmaceuticals, Inc. today announced final results from a Phase 1 trial. The primary purpose of this trial was to evaluate the safety and tolerability of OGX-427 up to doses of 1000 mg for the treatment of various solid tumors. Patients enrolled had a diagnosis of castrate resistant prostate cancer, breast cancer, ovarian cancer or non-small cell lung cancer.

More... (http://www.news-medical.net/news/20100608/Final-results-from-Phase-1-trial-of-OGX-427-for-treating-solid-tumors-presented-at-ASCO-2010.aspx)